Marty Shtrubel

About the Author Marty Shtrubel


MEI Pharma (MEIP) Stock Takes a Hit but This Analyst Keeps the Faith

Investors of MEI Pharma (MEIP) trudged off to the 4th of July celebrations in a downbeat mood. In last week’s final session, shares …

Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst

It was a difficult start to the week for Heron Therapeutics (HRTX). Monday saw shares plunge after the small-cap biotech received another CRL …

Is BlackBerry Stock a Buy Right Now? This Is What You Need To Know

Can BlackBerry (BB) become the stock market’s Liverpool FC? For anyone following the English Premier League, after 30 barren years and one global …

Nike Stock Will Surge 15% From Current Levels, Says Analyst

The coronavirus’ impact spares no one. Nike (NKE) surprised Wall Street on Friday, when the sportwear giant took a beating by COVID-19 in …

Zogenix’s Fintepla Gains FDA Approval, but Analyst Sees Challenging Launch Ahead

Last Friday was a forgettable one for drug maker Zogenix (ZGNX). Shares popped by 15% in early trading, only to end the day down …

Is Bitcoin Coming to PayPal? 5-Star Analyst Weighs In

Crypto could take another step towards mainstream adoption if new reports from CoinDesk turn out to be true. On June 22, unconfirmed reports …

Evoke Pharma Set to Gain 170%? This 5-Star Analyst Thinks So

Gastrointestinal disease-focused Evoke Pharma (EVOK) kicked off the week in style. Monday, June 22, saw shares go through the roof, and by the …

Uber: GrubHub Got Away, But There Are Other Opportunities to Consider

Uber (UBER) might have missed out on the highly-publicized GRUB acquisition, but there are other opportunities for the ride sharing pioneer. So believes …

Pluristem Is a High Risk, High Reward Play, Says Jefferies Analyst

Just how high can Pluristem Therapeutics (PSTI) climb? The Israeli biotech has outperformed in 2020, with shares up by 94% year-to-date.

CONTEPO CRL Is a Blow for Cash-Strapped Nabriva (NBRV), Says Analyst

The FDA’s equivalent of a red card – a CRL (complete response letter) – got handed out on June 19 to Nabriva Therapeutics …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts